ý

Feature Channels: Genetics

Filters close
Go to Advanced Search
access_time Embargo lifts in 2 days
This news release is embargoed until 2-May-2025 11:00 AM EDT Released to reporters: 29-Apr-2025 7:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 2-May-2025 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: AI-Based Liquid Biopsy Shows Promise for Detecting Brain Cancer
Released: 29-Apr-2025 11:05 AM EDT
AI-Based Liquid Biopsy Shows Promise for Detecting Brain Cancer
Johns Hopkins Medicine

A new liquid biopsy approach developed by Johns Hopkins Kimmel Cancer Center investigators could revolutionize brain cancer detection by identifying circulating DNA fragments from tumors and immune cells in blood samples, potentially enabling earlier diagnosis.

Released: 29-Apr-2025 9:50 AM EDT
Metabolon Launches Microbiome Research Solution Combining New Microbiome Panel, Metagenomics Sequencing, and Multiomics Bioinformatics Tools
Metabolon, Inc.

Metabolon Launches Microbiome Research Solution Combining New Microbiome Panel, Metagenomics Sequencing, and Multiomics Bioinformatics Tools

Released: 29-Apr-2025 7:10 AM EDT
Nabsys Achieves ISO 9001:2015 Certification, Reinforcing Commitment to Quality and Excellence
Nabsys

Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping technology, announces its achievement of ISO 9001:2015 certification. This internationally recognized standard demonstrates Nabsys' dedication to maintaining a robust and effective quality management system.

Released: 28-Apr-2025 6:05 PM EDT
Largest Osteoarthritis Genetic Study Uncovers Pathways to New Therapies and Repurposed Drugs
RUSH

Researchers have uncovered multiple new genes and genetic pathways that could lead to repurposing hundreds of existing drugs for osteoarthritis, the most common form of arthritis.

access_time Embargo lifts in 2 days
This news release is embargoed until 30-Apr-2025 11:00 AM EDT Released to reporters: 28-Apr-2025 5:25 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 30-Apr-2025 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Researchers Say a Genetic Mutation and Evolutionary Trick Makes Horses Athletic, Finding May Spur Treatments for Human Disease
Released: 28-Apr-2025 10:35 AM EDT
Researchers Say a Genetic Mutation and Evolutionary Trick Makes Horses Athletic, Finding May Spur Treatments for Human Disease
Johns Hopkins Medicine

How did horses become some of the greatest athletes in the animal kingdom? Researchers at Johns Hopkins Medicine may have found the answer, pinpointing a genetic mutation and evolutionary process that occurred millions of years ago, which appears to have optimized horses’ speeds and stamina.

Newswise: AACR: First-in-Class Covalent Werner Helicase Inhibitor Shows Clinical Proof-of-Concept in Phase I Trial
Released: 27-Apr-2025 4:30 PM EDT
AACR: First-in-Class Covalent Werner Helicase Inhibitor Shows Clinical Proof-of-Concept in Phase I Trial
University of Texas MD Anderson Cancer Center

• RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors • Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors • This class of drugs is important because many solid tumor patients with microsatellite instability (MSI) do not benefit from currently approved immunotherapies • Encouraging early results in this first-in-human trial prompted additional trial cohorts to optimize recommended dose for future clinical development

Newswise: AACR: Olaparib and Pembrolizumab Combination Shows Early Promise in Molecularly Selected, Tumor-Agnostic Trial
Released: 27-Apr-2025 2:00 PM EDT
AACR: Olaparib and Pembrolizumab Combination Shows Early Promise in Molecularly Selected, Tumor-Agnostic Trial
University of Texas MD Anderson Cancer Center

• Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations • Combination demonstrated complete responses and partial responses in different cancer types, including those beyond the currently approved indications for these therapies

Newswise: KIAA1199: A New Player in Adipogenesis and Whole-Body Energy Regulation
Released: 27-Apr-2025 4:00 AM EDT
KIAA1199: A New Player in Adipogenesis and Whole-Body Energy Regulation
Chinese Academy of Sciences

A recent study has revealed that KIAA1199, a secreted protein produced by bone marrow cells, plays a crucial role in regulating both fat formation and overall energy metabolism. The protein's impact extends beyond bone remodeling, influencing glucose and lipid metabolism. Mice lacking KIAA1199 showed reduced fat mass, improved insulin sensitivity, and a decreased risk of obesity-related diseases. These findings suggest that targeting KIAA1199 could lead to new therapeutic strategies for combating metabolic disorders like obesity and type 2 diabetes.

access_time Embargo lifts in 2 days
This news release is embargoed until 30-Apr-2025 5:00 PM EDT Released to reporters: 25-Apr-2025 6:15 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 30-Apr-2025 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 25-Apr-2025 10:20 AM EDT
Wren Laboratories Receives NYSDOH-CLEP Approval for PROSTest™, Transforming Prostate Cancer Detection
Wren Laboratories

Wren Laboratories, a leader in molecular diagnostics, is proud to announce that its breakthrough liquid biopsy test, PROSTest™, has been approved by the New York State Department of Health Clinical Laboratory Evaluation Program (NYSDOH-CLEP).

Released: 23-Apr-2025 5:40 PM EDT
Monell Center Presentations Span Sensory Science at National Meeting, April 23 to 26, 2025
Monell Chemical Senses Center

Over 20 scientists from the Monell Chemical Senses Center will present their latest research at the 47th Association for Chemoreception Sciences annual conference, which covers the latest advances in the fields of taste, smell, and related chemical senses. Monell researchers are chairing and participating in oral presentation sessions as well as sharing close to 20 posters over three days. Several Monellians will also receive annual awards from AChemS for their research achievements, highlighted below.

Released: 23-Apr-2025 11:40 AM EDT
Mayo Clinic Researchers Link Inherited Mutation to Fatty Liver Disease
Mayo Clinic

Researchers at Mayo Clinic's Center for Individualized Medicine have discovered a rare genetic variant that can directly cause metabolic dysfunction-associated steatotic liver disease, formerly known as nonalcoholic fatty liver disease.

Newswise: Parts of Our DNA May Evolve Much Faster than Previously Thought
Released: 23-Apr-2025 11:00 AM EDT
Parts of Our DNA May Evolve Much Faster than Previously Thought
University of Utah Health

A team of researchers has used advanced DNA sequencing to develop the most comprehensive atlas yet of genetic change through generations, laying the foundations for new insights into the roots of human disease and evolution.

   
Released: 23-Apr-2025 11:00 AM EDT
Childhood Exposure to Bacterial Toxin May Be Triggering Colorectal Cancer Epidemic Among the Young
University of California San Diego

An international team led by the University of California San Diego has identified a potential microbial culprit behind the alarming rise in early-onset colorectal cancer: a bacterial toxin called colibactin.

   
Released: 23-Apr-2025 6:05 AM EDT
ProBio Announces Six Presentations at American Society of Gene and Cell Therapy 28th Annual Meeting 2025
ProBio Inc.

ProBio, a global contract development and manufacturing organization (CDMO), announced that it will present six poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13–15, 2025, in New Orleans, LA.

Released: 22-Apr-2025 5:50 PM EDT
Mayo Clinic Uncovers Brain Cell Changes That Could Explain Tourette Syndrome
Mayo Clinic

A new Mayo Clinic study finds that people with Tourette syndrome have about half as many of a specific type of brain cell that helps calm overactive movement signals as people without the condition. This deficit may be a key reason why their motor signals go unchecked, leading to the involuntary tics that define the disorder.

Released: 22-Apr-2025 9:00 AM EDT
First New Subtype of Castleman Disease Discovered in 45 Years
Perelman School of Medicine at the University of Pennsylvania

A newly identified subtype of Castleman disease will help diagnose and properly treat thousands of patients who have been caught between existing classification systems, marking the first major discovery of its kind in 45 years. "Oligocentric Castleman Disease" (OligoCD) has been found to be a distinct clinical entity, different from the two previously identified classifications of Castleman Disease. The findings, which redefine the understanding of this rare immune disorder that affects an estimated 4,300 to 5,200 Americans, are published this week in Blood Advances by researchers from the Perelman School of Medicine at the University of Pennsylvania.

Released: 21-Apr-2025 8:05 PM EDT
Building ‘Cellular Bridges’ for Spinal Cord Repair After Injury
Ohio State University

Capitalizing on the flexibility of tiny cells inside the body’s smallest blood vessels may be a powerful spinal cord repair strategy, new research suggests.



close
3.21825